ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MBIO Mustang Bio Inc

0.2331
-0.0069 (-2.87%)
Last Updated: 15:44:39
Delayed by 15 minutes

Period:

Draw Mode:

Volume 8,948,259
Bid Price 0.233
Ask Price 0.2331
News -
Day High 0.2549

Low
0.205

52 Week Range

High
8.17

Day Low 0.205
Company Name Stock Ticker Symbol Market Type
Mustang Bio Inc MBIO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0069 -2.87% 0.2331 15:44:39
Open Price Low Price High Price Close Price Prev Close
0.249 0.205 0.2549 0.24
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
15,877 8,948,259 $ 0.233446 $ 2,088,935 - 0.205 - 8.17
Last Trade Time Type Quantity Stock Price Currency
15:44:42 1 $ 0.233 USD

Mustang Bio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
2.39M 10.39M - 0 -51.6M -4.97 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Mustang Bio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No MBIO Message Board. Create One! See More Posts on MBIO Message Board See More Message Board Posts

Historical MBIO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.2660.43880.2050.248062810,502,671-0.0329-12.37%
1 Month0.36370.43880.2050.24935392,778,528-0.1306-35.91%
3 Months1.331.490.2050.37623211,151,339-1.10-82.47%
6 Months1.561.680.2050.4261338576,784-1.33-85.06%
1 Year4.338.170.2050.7154055316,284-4.10-94.62%
3 Years49.0560.900.20521.82658,164-48.82-99.52%
5 Years54.1589.700.20539.10873,423-53.92-99.57%

Mustang Bio Description

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors.